Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.

MLA

Bandyopadhyay, Ananda S., et al. “Safety and Immunogenicity of Inactivated Poliovirus Vaccine Schedules for the Post-Eradication Era: A Randomised Open-Label, Multicentre, Phase 3, Non-Inferiority Trial.” The Lancet. Infectious Diseases, vol. 21, no. 4, Apr. 2021, pp. 559–68. EBSCOhost, https://doi.org/10.1016/S1473-3099(20)30555-7.

APA

Bandyopadhyay, A. S., Gast, C., Rivera, L., Sáez-Llorens, X., Oberste, M. S., Weldon, W. C., Modlin, J., Clemens, R., Costa Clemens, S. A., Jimeno, J., & Rüttimann, R. (2021). Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. The Lancet. Infectious Diseases, 21(4), 559–568. https://doi.org/10.1016/S1473-3099(20)30555-7

Chicago

Bandyopadhyay, Ananda S, Chris Gast, Luis Rivera, Xavier Sáez-Llorens, M Steven Oberste, William C Weldon, John Modlin, et al. 2021. “Safety and Immunogenicity of Inactivated Poliovirus Vaccine Schedules for the Post-Eradication Era: A Randomised Open-Label, Multicentre, Phase 3, Non-Inferiority Trial.” The Lancet. Infectious Diseases 21 (4): 559–68. doi:10.1016/S1473-3099(20)30555-7.